Newer TNF blockers (etanercept, infliximab and adalimumab) have contributed greatly to the
control of chronic inflammatory disease. Many of the damaging inflammatory mechanisms …

OBJECTIVE: To review the benefits and risks associated with the use of the tumor necrosis
factor (TNF)-blockers in various indications (eg, rheumatoid arthritis [RA], Crohn's disease …

Objective To compare the efficacy and safety of adalimumab plus methotrexate (MTX)
versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive …

Objective To investigate the impact of official recommendations regarding the management
of latent tuberculosis (TB) infection on the rate of active TB in patients receiving treatment …

Tina Ding1, Jo Ledingham2, Raashid Luqmani3, Sarah Westlake4, Kimme Hyrich5, Mark
Lunt5, Patrick Kiely6, Marwan Bukhari7, Rikki Abernethy8, Ailsa Bosworth9, Andrew …

Background The recommendations for detecting latent tuberculosis infection (LTBI) before
antitumour necrosis factor (anti-TNF) therapy are based on the tuberculin skin test (TST) …

Autophagy plays an important role in protecting the host against pathogens. Mycobacterium
tuberculosis can suppress autophagy and then remain dormant and survive within the host …

Background Tumour necrosis factor (TNF)‐alpha inhibitors are a major advance in the
management of inflammatory bowel disease but increase the risk for tuberculosis (TB). Aim …

Introduction: Latent tuberculosis infection (LTBI) is detected with the tuberculin skin test
(TST) before anti-TNF therapy. We aimed to investigate in vitro blood assays with TB-specific …

Tuberculosis risk is increased in patients with chronic inflammatory diseases receiving any
immunosuppressive treatment, notably tumor necrosis factor (TNF) antagonists therapy …